• No se han encontrado resultados

Module XlXCost efficacy and costbenefit of treatment of hepatitis C

N/A
N/A
Protected

Academic year: 2020

Share "Module XlXCost efficacy and costbenefit of treatment of hepatitis C"

Copied!
5
0
0

Texto completo

Loading

Figure

Table II. Increasing relationship cost effectiveness and relation incremental cost with an annual discount rate of 3% for various management

Referencias

Documento similar

The notion of parallel cost P corresponds to the cost consumed between the first instruction executed by the program at the initial location and the last instruction executed at

This paper reviews the current available bone targeting drug delivery systems, focusing on nanoparticles, proposed for osteoporosis treatment.. Bone targeting delivery systems is

Effectiveness of Day Hospital Mentalization-Based Treatment for Patients with Severe Borderline Personality Disorder: A Matched Control Study.. Treatment of Borderline

For the economic evidence, systematic reviews and primary studies of resource use, costs or cost-effectiveness of screening for schistosomiasis or strongyloidiasis with or

Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis...

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL):

EIRA study will determine the effectiveness and cost- effectiveness of a complex multiple risk intervention and will provide a better understanding of implementation processes of